Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Newlink Genetics Cor (NLNK)

Newlink Genetics Cor (NLNK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 59,702
  • Shares Outstanding, K 37,314
  • Annual Sales, $ 12,470 K
  • Annual Income, $ -53,600 K
  • 60-Month Beta 1.03
  • Price/Sales 4.67
  • Price/Cash Flow N/A
  • Price/Book 0.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.28
  • Number of Estimates 1
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year -0.28
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.36 +19.56%
on 10/21/19
1.64 -1.22%
on 11/20/19
+0.25 (+18.25%)
since 10/18/19
3-Month
1.13 +43.36%
on 10/02/19
2.10 -22.86%
on 09/18/19
+0.03 (+1.89%)
since 08/20/19
52-Week
1.13 +43.36%
on 10/02/19
2.27 -28.63%
on 03/19/19
-0.24 (-12.90%)
since 11/20/18

Most Recent Stories

More News
NewLink Genetics Announces European Commission Grant of Conditional Marketing Approval for Ebola Vaccine V920 (ERVEBO(R))

NewLink Genetics Corporation (NASDAQ:NLNK) announced that Monday, November 11, the European Commission (EC) granted a conditional marketing authorization to ERVEBO(R), investigational V920 Ebola Zaire...

NLNK : 1.59 (-0.63%)
MRK : 84.68 (+0.04%)
NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on corporate activities.

NLNK : 1.59 (-0.63%)
MRK : 84.68 (+0.04%)
NewLink Genetics to Host Its Third Quarter 2019 Conference Call on November 6, 2019

NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its third quarter 2019 conference call and webcast at 8:30 AM ET on Wednesday, November 6, 2019, to discuss its third quarter financial...

NLNK : 1.59 (-0.63%)
NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO(R))

NewLink Genetics Corporation (NASDAQ:NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion...

NLNK : 1.59 (-0.63%)
MRK : 84.68 (+0.04%)
Zika Vaccines Market 2019: by Company Profile, Deals Type, Funding, Clinical Trials Insight

helps in immunization and prevention against the diseases caused by Zika virus. Aedes mosquitoes are the source of this virus that belongs to genus Flavivirus. Blood transfusion and sexual contact can...

CERS : 4.39 (+1.62%)
GSK : 43.98 (-1.17%)
IMV.TO : 3.10 (+0.65%)
INO : 2.49 (+5.06%)
NLNK : 1.59 (-0.63%)
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases

-- Combined company to assume the name, Lumos Pharma, Inc. and is expected to be led by Richard J. Hawkins, current CEO of Lumos Pharma --

NLNK : 1.59 (-0.63%)
Company News For Sep 19, 2019

Companies in the news are: FDX, BYND, SPI, NLNK

NLNK : 1.59 (-0.63%)
FDX : 153.72 (-1.16%)
BYND : 78.15 (+1.03%)
SPI : 2.37 (+4.18%)
Stock to Watch: Newlink Genetics Up 7.9% (NLNK)

Newlink Genetics (NASDAQ:NLNK) is one of today's best performing low-priced stocks, up 7.9% to $2.06 on 5.5x average daily volume. Thus far today, Newlink Genetics has traded 1.2 million shares, vs. average...

NLNK : 1.59 (-0.63%)
Thinking about buying stock in Aurora Cannabis, DavidsTea, NewLink Genetics, SINTX Technologies, or Spi Energy?

InvestorsObserver issues critical PriceWatch Alerts for ACB, DTEA, NLNK, SINT, and SPI.

ACB.TO : 3.43 (+10.29%)
DTEA : 1.50 (+0.65%)
NLNK : 1.59 (-0.63%)
SINT : 1.61 (-6.94%)
SPI : 2.37 (+4.18%)
NewLink Genetics Announces FDA Accepts Partnered Biologics License Application (BLA) and Grants Priority Review for Ebola Vaccine V920 (rVSVDG-ZEBOV-GP)

NewLink Genetics Corporation (NASDAQ:NLNK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Merck's Biologics License Application (BLA) and granted priority review for the...

MRK : 84.68 (+0.04%)
NLNK : 1.59 (-0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade NLNK with:

Business Summary

NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink...

See More

Key Turning Points

2nd Resistance Point 1.65
1st Resistance Point 1.63
Last Price 1.59
1st Support Level 1.57
2nd Support Level 1.53

See More

52-Week High 2.27
Fibonacci 61.8% 1.83
Fibonacci 50% 1.70
Last Price 1.59
Fibonacci 38.2% 1.57
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar